Pheast Therapeutics may have learned the hard way about the risks of competitors getting a glimpse of your heard-earned discoveries, but the immuno-oncology startup is so far sticking to its transparent approach.
Pheast Therapeutics may have learned the hard way about the risks of competitors getting a glimpse of your heard-earned discoveries, but the immuno-oncology startup is so far sticking to its transparent approach.
